tiprankstipranks
Advertisement
Advertisement
Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
PremiumRatingsJanux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
30d ago
Janux Therapeutics reports Q4 EPS (51c), consensus (64c)
Premium
The Fly
Janux Therapeutics reports Q4 EPS (51c), consensus (64c)
1M ago
Janux Therapeutics doses first patient in JANX011 trial
Premium
The Fly
Janux Therapeutics doses first patient in JANX011 trial
1M ago
Janux Therapeutics downgraded to Hold from Buy at Clear Street
PremiumThe FlyJanux Therapeutics downgraded to Hold from Buy at Clear Street
2M ago
Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler
Premium
The Fly
Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler
2M ago
Janux Therapeutics price target lowered to $35 from $49 at BofA
Premium
The Fly
Janux Therapeutics price target lowered to $35 from $49 at BofA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100